2015
DOI: 10.1016/s0959-8049(16)31932-3
|View full text |Cite
|
Sign up to set email alerts
|

8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 0 publications
0
7
0
Order By: Relevance
“…Regardless of the radiation schedule employed, the data show comparable diseasefree survival (DFS) and similar toxicity rates at the available time points, thus confirming the noninferiority of hypofractionation over conventional regimens -at least at relatively early time points [29][30][31] . Mature results from complementary non inferiority trials are pending and will help to clarify the role of moderately hypofractionated radiotherapy for organconfined prostate cancer.…”
Section: Fiducial Markersmentioning
confidence: 83%
See 2 more Smart Citations
“…Regardless of the radiation schedule employed, the data show comparable diseasefree survival (DFS) and similar toxicity rates at the available time points, thus confirming the noninferiority of hypofractionation over conventional regimens -at least at relatively early time points [29][30][31] . Mature results from complementary non inferiority trials are pending and will help to clarify the role of moderately hypofractionated radiotherapy for organconfined prostate cancer.…”
Section: Fiducial Markersmentioning
confidence: 83%
“…Noninferiority trials are currently ongoing to resolve the scientific debate. The clinical evidence seems to show that a shortened course of radiotherapy is as safe and effective as a long course of conventionally fractionated radiotherapy [29][30][31] , supporting current practice changing trends. Muchneeded robust evidence of the efficacy of hypo fractionation is currently being accrued in clini cal trials, but these studies run for long time periods and their results might have a limited effect on clinical practice by the time they are published.…”
Section: Future Perspectivesmentioning
confidence: 88%
See 1 more Smart Citation
“…Two of the trials were carried out before dose-escalation was known and therefore delivered insufficient dose ( 15 , 16 ). Three of the trials showed no significant difference reported in BFFR, OS, or toxicity compared with conventional fractionation for prostate cancer with median follow-up from 51 to 90 months ( 17 19 ). The recent 5-year data published from the non-inferiority HYPRO trial of intermediate- and high-risk patients concluded that dose-escalated moderate hypofractionation was not superior with comparable relapse-free survival but higher toxicity profiles compared with standard fractionation ( 20 , 21 ).…”
Section: Discussionmentioning
confidence: 98%
“…Radiotherapy clinical trials play a vital role in assessing new treatment fractionations, dose escalation regimes, chemo-radiation techniques, quality of life, toxicity and long-term survival 22 . Recent landmark prostate trials by Dearnaley et al led to a national change in radiotherapy delivery for low/intermediate prostate cancer patients 23 . The trial randomised more than 3,200 patients between 74 Gray in 37 fractions (control arm), 60 Gray in 20 fractions and 57 Gray in 19 fractions in combination with hormone therapy.…”
Section: Crr Role Developmentmentioning
confidence: 99%